JP2022520428A5 - - Google Patents

Info

Publication number
JP2022520428A5
JP2022520428A5 JP2021547336A JP2021547336A JP2022520428A5 JP 2022520428 A5 JP2022520428 A5 JP 2022520428A5 JP 2021547336 A JP2021547336 A JP 2021547336A JP 2021547336 A JP2021547336 A JP 2021547336A JP 2022520428 A5 JP2022520428 A5 JP 2022520428A5
Authority
JP
Japan
Prior art keywords
sequence
ribonucleic acid
manipulated
composition according
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021547336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022520428A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/018432 external-priority patent/WO2020168291A1/en
Publication of JP2022520428A publication Critical patent/JP2022520428A/ja
Publication of JP2022520428A5 publication Critical patent/JP2022520428A5/ja
Priority to JP2023146414A priority Critical patent/JP7502537B2/ja
Priority to JP2024091759A priority patent/JP2024133476A/ja
Ceased legal-status Critical Current

Links

JP2021547336A 2019-02-14 2020-02-14 Ruvcドメインを有する酵素 Ceased JP2022520428A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023146414A JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素
JP2024091759A JP2024133476A (ja) 2019-02-14 2024-06-05 Ruvcドメインを有する酵素

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201962805878P 2019-02-14 2019-02-14
US201962805899P 2019-02-14 2019-02-14
US201962805868P 2019-02-14 2019-02-14
US62/805,868 2019-02-14
US62/805,899 2019-02-14
US62/805,878 2019-02-14
US201962874414P 2019-07-15 2019-07-15
US62/874,414 2019-07-15
PCT/US2020/018432 WO2020168291A1 (en) 2019-02-14 2020-02-14 Enzymes with ruvc domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023146414A Division JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素

Publications (2)

Publication Number Publication Date
JP2022520428A JP2022520428A (ja) 2022-03-30
JP2022520428A5 true JP2022520428A5 (enExample) 2023-02-21

Family

ID=72045639

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021547336A Ceased JP2022520428A (ja) 2019-02-14 2020-02-14 Ruvcドメインを有する酵素
JP2023146414A Active JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素
JP2024091759A Pending JP2024133476A (ja) 2019-02-14 2024-06-05 Ruvcドメインを有する酵素

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023146414A Active JP7502537B2 (ja) 2019-02-14 2023-09-08 Ruvcドメインを有する酵素
JP2024091759A Pending JP2024133476A (ja) 2019-02-14 2024-06-05 Ruvcドメインを有する酵素

Country Status (9)

Country Link
US (1) US20240117330A1 (enExample)
EP (1) EP3924482A4 (enExample)
JP (3) JP2022520428A (enExample)
KR (2) KR20240007322A (enExample)
CN (2) CN116515797A (enExample)
AU (3) AU2020223370B2 (enExample)
CA (2) CA3241703C (enExample)
MX (2) MX2021009886A (enExample)
WO (1) WO2020168291A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021178933A2 (en) 2020-03-06 2021-09-10 Metagenomi Ip Technologies, Llc Class ii, type v crispr systems
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
AU2019291918B2 (en) 2018-06-29 2025-06-12 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
KR20240007322A (ko) * 2019-02-14 2024-01-16 메타지노미, 인크. Ruvc 도메인이 존재하는 효소
US10913941B2 (en) 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
GB2617659B (en) * 2020-02-14 2024-05-01 Metagenomi Inc Enzymes with RuvC domains
CA3177051A1 (en) * 2020-03-31 2021-10-07 Metagenomi, Inc. Class ii, type ii crispr systems
CN116096892A (zh) * 2020-05-08 2023-05-09 宏基因组学公司 具有RuvC结构域的酶
WO2021226369A1 (en) * 2020-05-08 2021-11-11 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
CA3192224A1 (en) 2020-09-11 2022-03-17 Jyun-Liang LIN Base editing enzymes
GB202418708D0 (en) * 2020-09-11 2025-02-05 Metagenomi Inc Base editing enzymes
JP2023546694A (ja) * 2020-10-21 2023-11-07 エメンドバイオ・インコーポレイテッド 新規のomni56、58、65、68、71、75、78及び84crisprヌクレアーゼ
EP4240853A2 (en) * 2020-11-03 2023-09-13 Science Solutions LLC Novel class 2 crispr-cas rna-guided endonucleases
CN116964197A (zh) * 2021-01-22 2023-10-27 宏基因组学公司 新型工程化和嵌合核酸酶
WO2022159742A1 (en) * 2021-01-22 2022-07-28 Metagenomi, Inc Novel engineered and chimeric nucleases
KR20230134543A (ko) * 2021-01-22 2023-09-21 메타지노미, 인크. 신규한 조작된 뉴클레아제 및 키메라 뉴클레아제
JP7877351B2 (ja) * 2021-03-19 2026-06-22 メタゲノミ セラピューティクス,インク. Cas酵素を用いたマルチプレックス編集
EP4330386A4 (en) * 2021-04-30 2025-05-14 Metagenomi, Inc. Enzymes with ruvc domains
CN119452085A (zh) * 2021-08-27 2025-02-14 宏基因组学公司 具有ruvc结构域的酶
MX2024005505A (es) 2021-11-05 2024-05-23 Metagenomi Inc Enzimas de edicion de bases.
KR20240110603A (ko) 2021-11-24 2024-07-15 메타지노미, 인크. 엔도뉴클레아제 시스템
WO2023122663A2 (en) * 2021-12-23 2023-06-29 Mammoth Biosciences, Inc. Effector proteins and methods of use
WO2023194359A1 (en) * 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
KR20250037788A (ko) * 2022-06-15 2025-03-18 빔 테라퓨틱스, 인크. 보체 활성화를 감소시키기 위한 조성물 및 방법
EP4587564A2 (en) * 2022-09-16 2025-07-23 Alia Therapeutics Srl Enqp type ii cas proteins and applications thereof
AU2024230342A1 (en) * 2023-03-01 2025-10-16 Metagenomi Therapeutics, Inc. Enzymes with ruvc domains
WO2025106934A1 (en) * 2023-11-16 2025-05-22 Metagenomi, Inc. Enzymes with ruvc domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105209621B (zh) * 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
US10392607B2 (en) * 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
WO2018035250A1 (en) * 2016-08-17 2018-02-22 The Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
KR20200124702A (ko) * 2018-02-23 2020-11-03 파이어니어 하이 부렛드 인터내쇼날 인코포레이팃드 신규한 cas9 오르소로그
KR20240007322A (ko) 2019-02-14 2024-01-16 메타지노미, 인크. Ruvc 도메인이 존재하는 효소

Similar Documents

Publication Publication Date Title
JP2023519953A5 (enExample)
JP2023517041A5 (enExample)
JP2024541402A5 (enExample)
JP2024535672A5 (enExample)
US20230123754A1 (en) RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
JP2022531347A5 (enExample)
CN111836894B (zh) 用于使用CRISPR/Cpf1系统进行基因组编辑的组合物及其用途
JP2023540797A5 (enExample)
Sampson et al. Exploiting CRISPR/C as systems for biotechnology
JP2021530988A5 (enExample)
Gryaznov Oligonucleotide N3′→ P5′ Phosphoramidates and Thio‐Phoshoramidates as Potential Therapeutic Agents
JP2019524149A5 (enExample)
CN115697420A (zh) 一种治疗赫勒氏综合征的方法和药物
JP2022046466A (ja) 核酸ガイド化ヌクレアーゼをベースとした系を使用する核酸の捕捉
JP2024517607A5 (enExample)
JP2020512845A5 (enExample)
CN106554969A (zh) 基于抑菌杀菌的多靶点CRISPR/Cas9表达载体
JP2015534817A5 (enExample)
RU2015128098A (ru) Конструирование систем, способы и оптимизированные направляющие композиции для манипуляции с последовательностями
JP2016502858A5 (enExample)
WO2013141680A1 (en) RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
RU2022103641A (ru) Искусственная модификация генома для регуляции экспрессии гена
JP2023542976A5 (enExample)
JP2021522825A5 (enExample)
JP2024500036A5 (enExample)